Lyerly, Herbert

Recent Publications

Osada, T, Hartman, ZC, Wei, J, Lei, G, Hobeika, AC, Gwin, WR, Diniz, MA, Spector, N, Clay, TM, Chen, W, Morse, MA, & Lyerly, HK. (2018, August 9). Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Research : Bcr, 20 (1), 90-null.

Forbes, NS, Coffin, RS, Deng, L, Evgin, L, Fiering, S, Giacalone, M, Gravekamp, C, Gulley, JL, Gunn, H, Hoffman, RM, Kaur, B, Liu, K, Lyerly, HK, Marciscano, AE, Moradian, E, Ruppel, S, Saltzman, DA, Tattersall, PJ, Thorne, S, Vile, RG, Zhang, HH, Zhou, S, & McFadden, G. (2018, August 6). White paper on microbial anti-cancer therapy and prevention. Journal for Immunotherapy of Cancer, 6 (1), 78-null.

Zhou, X, Qiao, G, Wang, X, Song, Q, Morse, MA, Hobeika, A, Gwin, WR, Ren, J, & Lyerly, HK. (2018, February). CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine. Cancer chemotherapy and pharmacology, 81 (2), 365-372.

Stilwell, JL, Hobeida, A, Birse, RT, Ericson, N, Ramirez, AB, Hummel, S, Irwin, D, Kaldjian, EP, & Lyerly, HK. (2018, February). Detection of mutations in single tumor cells collected by fine needle aspiration in a mouse xenograft breast cancer model using MALDI-TOF.

Crosby, EJ, Wei, J, Yang, XY, Lei, G, Wang, T, Liu, C-X, Agarwal, P, Korman, AJ, Morse, MA, Gouin, K, Knott, SRV, Lyerly, HK, & Hartman, ZC. (2018, January 19). Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors. Oncoimmunology, 7 (5), e1421891-null.

Song, Q, Ren, J, Zhou, X, Wang, X, Song, G, Hobeika, A, Yuan, Y, & Lyerly, HK. (2018, January). Circulating CD8+CD28- suppressor T cells tied to poorer prognosis among metastatic breast cancer patients receiving adoptive T-cell therapy: A cohort study. Cytotherapy, 20 (1), 126-133.

Shuptrine, CW, Ajina, R, Fertig, EJ, Jablonski, SA, Kim Lyerly, H, Hartman, ZC, & Weiner, LM. (2017, December). An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer immunology, immunotherapy : CII, 66 (12), 1529-1544.

Osada, T, Kaneko, K, Gwin, WR, Morse, MA, Hobeika, A, Pogue, BW, Hartman, ZC, Hughes, PF, Haystead, T, & Lyerly, HK. (2017, December). In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23 (24), 7531-7542.

Jiang, N, Qiao, G, Wang, X, Morse, MA, Gwin, WR, Zhou, L, Song, Y, Zhao, Y, Chen, F, Zhou, X, Huang, L, Hobeika, A, Yi, X, Xia, X, Guan, Y, Song, J, Ren, J, & Lyerly, HK. (2017, September). Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 23 (17), 5066-5073.

Osada, T, Kaneko, K, Hartman, Z, Hobeika, A, Hughes, P, Haystead, T, Morse, M, & Lyerly, HK. (2017, July 1). Abstract 1859: Hsp90 targeted near infrared molecular imaging to detect mammografically occult invasive lobular breast cancer.

View All Publications

Herbert Lyerly

Summary

Recent Publications